Abstract
Aim. To study efficacy and tolerability of isosorbide-5-mononitrate (IMN) in various presentations in comparison with isosorbide dinitrate (IDN) in usual tablets in patients with stable angina. Material and Methods. 22 patients (5 women and 17 men) with stable angina of II-III functional class were involved into open randomized comparative crossover study. Patients were split in 3 groups and received each of studied drugs during 4 weeks. IDN (Nitrosorbide, Nizpharm, Russia) in usual tablets 10 mg prescribed for 3 times a day administration; IMN (Monocinque,Berlin-Chemie, German) in tablets 20 mg prescribed for 2 times a day administration. After 1 week therapy the doses of IDN or IMN doubled if it was clinically necessary. Retarded presentation of IMN (Monocinque Retard, Berlin-Chemie, German) in capsules 50 mg prescribed once daily. Drug efficacy was evaluated by changes in clinical symptoms, number of angina attacks, demand in short-acting sublingual nitroglycerin as well as physical activity tolerance. Results. After 4 weeks 18 patients completed study, 2 patients dropped out because of protocol nonobservance and 2 patients dropped out because of side effects (headache). IDN therapy in adjusted dose provided antianginal effect in 15 (83,3%) patients: a number of angina attacks decreased in 39,6%, short-acting nitroglycerin demand reduced in 47,7%. Monocinque in adjusted dose provided antianginal effect in 16 (88,9%) patients: a number of angina attacks decreased in 60%, short-acting nitroglycerin demand reduced in 63%. Monocinque Retard provided good antianginal effect in 18 (100%) patients: a number of angina attacks decreased in 72%, short-acting nitroglycerin demand reduced in 84,8%. There were not significant differences in frequency and severity of headache between studied drugs. Conclusion. IMN therapy with both presentations (administrated 1 or 2 times a day) was more convenient and effective than IDN (administrated 3 times a day).
Highlights
Выбор терапии нитратами у больных стабильной стенокардией напряжения: сравнительное исследование обычных таблеток изосорбида динитрата и различных лекарственных форм изосорбид-5-мононитрата В.А
isosorbide dinitrate (IDN) therapy in adjusted dose provided antianginal effect in 15 (83,3%) patients: a number of angina attacks decreased in 39,6%, short-acting nitroglycerin demand reduced in 47,7%
Monocinque in adjusted dose provided antianginal effect in 16 (88,9%) patients: a number of angina attacks decreased in 60%, short-acting nitroglycerin demand reduced in 63%
Summary
Государственный научно-исследовательский центр профилактической медицины Росмедтехнологий, Москва. Выбор терапии нитратами у больных стабильной стенокардией напряжения: сравнительное исследование обычных таблеток изосорбида динитрата и различных лекарственных форм изосорбид-5-мононитрата В.А. Изучить эффективность и переносимость различных лекарственных форм изосорбид-5-мононитрата (ИМН) у больных со стабильной стенокардией напряжения в сравнении со стандартной терапией обычными таблетками изосорбида динитрата (ИДН). Моночинкве в подобранной дозе был эффективен у 16 (88,9%) больных: число приступов стенокардии через 4 недели терапии снизилось на 60%, потребность в приёме коротко действующего нитроглицерина сократилась на 63%. Хорошая антиангинальная эффективность при приеме Моночинкве ретард отмечалась у 18 (100%) больных: число приступов стенокардии через 4 нед снизилось на 72%, потребность в приёме коротко действующего нитроглицерина снизилась в группе на 84,8%. IDN therapy in adjusted dose provided antianginal effect in 15 (83,3%) patients: a number of angina attacks decreased in 39,6%, short-acting nitroglycerin demand reduced in 47,7%. Это создает достаточно большие трудности для практических врачей при назначении терапии, в связи с чем выбор для конкретного больного нередко оказывается неоптимальным: назначается либо недостаточно эффективная, либо недостаточно удобная терапия [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
